Skip to main content

Advertisement

Table 4 Univariate and multivariate analysis according to the various criteria

From: Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer

Factors Univariate analysis P
Age 1.022 (1.033–1.042) 0.021
Sex 0.823 (0.545–1.245) 0.357
Tumor size 1.150 (1.058–1.251) 0.001
Histologic grade (high vs. low) 3.582 (2.136–6.007) <0.001
Tumor border (infiltrative vs. expanding) 4.173 (1.532–11.365) 0.005
Lymphatic invasion (present vs. absent) 3.345 (2.039–5.488) <0.001
Venous invasion (present vs. absent) 3.777 (2.484–5.741) <0.001
Neural invasion (present vs. absent) 3.601 (2.389–5.427) <0.001
pTNM stage (IV vs. I–III) 7.727 (5.109–11.687) <0.001
Amplification in any gene (≥2 vs. <2) 1.235 (0.759–2.008) 0.395
GCN gain in any gene (≥4 vs. <4) 1.770 (1.175–2.666) 0.006
ASCO/CAP criteria in any gene (positive/equivocal vs. negative) 1.608 (1.067–2.421) 0.023
  1. MSI microsatellite instability, GCN gene copy number, ASCO/CAP American Society of Clinical Oncology/College of American Pathologists
Factors Multivariate analysis P
GCN gain
 Age 1.038 (1.015–1.061) 0.001
 Sex 0.643 (0.414–0.999) 0.049
 Tumor size 1.115 (1.001–1.243) 0.048
 Histologic grade (high vs. low) 2.843 (1.571–5.143) 0.001
 Tumor border (infiltrative vs. expanding) 2.550 (0.899–7.231) 0.078
 Lymphatic invasion (present vs. absent) 1.296 (0.737–2.276) 0.368
 Venous invasion (present vs. absent) 1.197 (0.720–1.989) 0.489
 Neural invasion (present vs. absent) 2.400 (1.506–3.827) <0.001
 pTNM stage (IV vs. I–III) 4.791 (2.891–7.940) <0.001
 GCN gain in any gene (≥4 vs. <4) 1.750 (1.145–2.673) 0.010
ASCO/CAP criteria
 Age 1.038 (1.016–1.061) 0.001
 Sex 0.645 (0.415–1.003) 0.052
 Tumor size 1.114 (0.999–1.241) 0.052
 Histologic grade (high vs. low) 2.857 (1.578–5.174) 0.001
 Tumor border (infiltrative vs. expanding) 2.525 (0.891–7.155) 0.081
 Lymphatic invasion (present vs. absent) 1.289 (0.734–2.265) 0.377
 Venous invasion (present vs. absent) 1.197 (0.721–1.987) 0.488
 Neural invasion (present vs. absent) 2.414 (1.514–3.850) <0.001
 pTNM stage (IV vs. I–III) 4.868 (2.941–8.057) <0.001
 ASCO/CAP criteria in any gene (positive/equivocal vs. negative) 1.676 (1.097–2.561) 0.017
  1. MSI microsatellite instability, GCN gene copy number, ASCO/CAP American Society of Clinical Oncology/College of American Pathologists